Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Sims

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Nature Immunology|October 21, 2010
IL-1 family nomenclatureCharles Dinarello, William Arend, John Sims, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Nature Immunology|October 21, 2010
IL-1 family nomenclatureCharles Dinarello, William Arend, John Sims, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Pageof 3